Population pharmacokinetics of valproate in Chinese children with epilepsy
- PMID: 17883957
- DOI: 10.1111/j.1745-7254.2007.00704.x
Population pharmacokinetics of valproate in Chinese children with epilepsy
Abstract
Aim: The aim of the present study is to establish a population pharmacokinetic (PPK) model of valproate (VPA) in Chinese epileptic children to promote the reasonable use of anti-epileptic drugs.
Methods: Sparse data of VPA serum concentrations from 417 epileptic children were collected. These patients were divided into 2 groups: the PPK model group (n=317) and the PPK valid group (n=100). The PPK parameter values of VPA were calculated by NONMEM software using the data of the PPK model group. A basic model and a final model were set up. To validate the 2 models, the concentrations of PPK valid group were predicted by each model, respectively. The mean prediction error (MPE), mean squared prediction error (MSPE), root mean squared prediction error (RMSPE), weight residues (WRES), and the 95% confidence intervals (95% CI) were also calculated. Then, the values between the 2 models were compared.
Results: The PPK of VPA was determined by a 1-compartment model with a first-order absorption process. The basic model was: Ka=3.09 (h(-1)), V/F=20.4 (L), CL/F=0.296 (L/h). The final model was: Ka=0.251+2.24 x (1-HS) (h(-1)), V/F=2.88+0.157 x WT (L), CL/F=0.106(0.98 x CO)+ 0.0157 x AGE (L/h). For the basic model, the MPE, MSPE, RMSPE, WRES, and the 95% CI were -23.53 (-30.36, -16.70), 3728.96 (2872.72, 4585.20), 39.62 (34.34, 44.90), and -0.06 (-0.14, 0.02), respectively. For the final model, the MPE, MSPE, RMSPE, WRES, and the 95% CI were -1.16 (-4.85, 2.53), 1002.83 (1050.64, 1143.61), 23.04 (21.12, 24.96), and 0.08 (-0.04, 0.20), respectively. The final model was more optimal than the basic model.
Conclusion: The PPK model of VPA in Chinese epileptic children was successfully established. It will be valuable to facilitate individualized dosage regimens.
Similar articles
-
Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy.Acta Pharmacol Sin. 2012 Jun;33(6):845-51. doi: 10.1038/aps.2012.57. Acta Pharmacol Sin. 2012. PMID: 22669118 Free PMC article.
-
Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy.Acta Pharmacol Sin. 2004 Dec;25(12):1576-83. Acta Pharmacol Sin. 2004. PMID: 15569400
-
Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):673-9. doi: 10.1358/mf.2007.29.10.1116313. Methods Find Exp Clin Pharmacol. 2007. PMID: 18200330
-
[The use of intravenous valproate].Rev Neurol. 1999 Oct 16-31;29(8):744-53. Rev Neurol. 1999. PMID: 10560111 Review. Spanish.
-
Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder.Expert Rev Clin Pharmacol. 2022 May;15(5):621-635. doi: 10.1080/17512433.2022.2075849. Epub 2022 Jun 2. Expert Rev Clin Pharmacol. 2022. PMID: 35536685
Cited by
-
Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy.Acta Pharmacol Sin. 2012 Jun;33(6):845-51. doi: 10.1038/aps.2012.57. Acta Pharmacol Sin. 2012. PMID: 22669118 Free PMC article.
-
Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study.Front Pharmacol. 2023 Oct 6;14:1228641. doi: 10.3389/fphar.2023.1228641. eCollection 2023. Front Pharmacol. 2023. PMID: 37869748 Free PMC article.
-
Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.Eur J Clin Pharmacol. 2009 Dec;65(12):1187-93. doi: 10.1007/s00228-009-0712-x. Epub 2009 Sep 16. Eur J Clin Pharmacol. 2009. PMID: 19756559
-
Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.Eur J Clin Pharmacol. 2018 Aug;74(8):1029-1036. doi: 10.1007/s00228-018-2440-6. Epub 2018 Apr 17. Eur J Clin Pharmacol. 2018. PMID: 29666902
-
A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.Eur J Clin Pharmacol. 2018 Jun;74(6):793-803. doi: 10.1007/s00228-018-2444-2. Epub 2018 Mar 21. Eur J Clin Pharmacol. 2018. PMID: 29564480
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical